TY - JOUR
T1 - Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone
AU - Tsimberidou, Apostolia M.
AU - Catovsky, Daniel
AU - Schlette, Ellen
AU - O'Brien, Susan
AU - Wierda, William G.
AU - Kantarjian, Hagop
AU - Garcia-Manero, Guillermo
AU - Wen, Sijin
AU - Do, Kim Anh
AU - Lerner, Susan
AU - Keating, Michael J.
PY - 2006/7/1
Y1 - 2006/7/1
N2 - BACKGROUND. The optimal management of patients with splenic marginal zone lymphoma/marginal zone lymphoma (SMZL) is controversial. The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone. METHODS. The Leukemia Service database was searched for patients with splenic lymphoma who were registered between May 1995 and October 2004. The indications fur treatment were the same as those used for patients with chronic lymphocytic leukemia. RESULTS. SMZL was confirmed in 70 patients. The median age was 64 years. The median number of CD20 molecules per cell was 69 × 103. Forty-three patients required systemic therapy; rituximab in 26 patients, chemotherapy plus rituximab in 6 patients, and chemotherapy alone in 11 patients. Ten additional patients underwent splenectomy, and 17 patients were in the observation group. The overall response rates were 88% with rituximab, 83% with rituximab plus chemotherapy, and 55% with chemotherapy alone; the 3-year survival rates were 95%, 100%, and 55%, respectively. The 3-year failure-free survival (FFS) rates were 86%, 100%, and 45% in the rituximab, rituximab plus chemotherapy, and chemotherapy alone groups, respectively. Rituximab treatments resulted in longer survival and FFS compared with chemotherapy. Rituximab alone resulted in disappearance of splenomegaly in 92% of patients and normalization of absolute lymphocyte counts. In univariate analysis, younger age and rituximab-based therapy were predictive of longer FFS. CONCLUSIONS. Rituximab with or without chemotherapy was found to have major activity in patients with SMZL. These results may be associated with high levels of cellular CD20 antigen sites. Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases.
AB - BACKGROUND. The optimal management of patients with splenic marginal zone lymphoma/marginal zone lymphoma (SMZL) is controversial. The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone. METHODS. The Leukemia Service database was searched for patients with splenic lymphoma who were registered between May 1995 and October 2004. The indications fur treatment were the same as those used for patients with chronic lymphocytic leukemia. RESULTS. SMZL was confirmed in 70 patients. The median age was 64 years. The median number of CD20 molecules per cell was 69 × 103. Forty-three patients required systemic therapy; rituximab in 26 patients, chemotherapy plus rituximab in 6 patients, and chemotherapy alone in 11 patients. Ten additional patients underwent splenectomy, and 17 patients were in the observation group. The overall response rates were 88% with rituximab, 83% with rituximab plus chemotherapy, and 55% with chemotherapy alone; the 3-year survival rates were 95%, 100%, and 55%, respectively. The 3-year failure-free survival (FFS) rates were 86%, 100%, and 45% in the rituximab, rituximab plus chemotherapy, and chemotherapy alone groups, respectively. Rituximab treatments resulted in longer survival and FFS compared with chemotherapy. Rituximab alone resulted in disappearance of splenomegaly in 92% of patients and normalization of absolute lymphocyte counts. In univariate analysis, younger age and rituximab-based therapy were predictive of longer FFS. CONCLUSIONS. Rituximab with or without chemotherapy was found to have major activity in patients with SMZL. These results may be associated with high levels of cellular CD20 antigen sites. Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases.
KW - Lymphoma
KW - Rituximab
KW - Splenectomy
KW - Splenic
KW - Splenic marginal zone lymphoma
UR - http://www.scopus.com/inward/record.url?scp=33745402382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745402382&partnerID=8YFLogxK
U2 - 10.1002/cncr.21931
DO - 10.1002/cncr.21931
M3 - Article
C2 - 16700034
AN - SCOPUS:33745402382
SN - 0008-543X
VL - 107
SP - 125
EP - 135
JO - Cancer
JF - Cancer
IS - 1
ER -